Skip to content
DataLookout
Menu

NCT07774611

An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 28 words
    • Start date changed from estimate of Sep 22, 2026 to Sep 18, 2026
    • Interventions: SG1827 (Drug), anti-PD-1/PD-L1 antibody (Drug), bevacizumab (Drug) to SG1827 (Drug), anti-PD-1/PD-L1 antibody (Drug), bevacizumab (Drug)
    • Site details revised at 10 of 10 sites
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

AEs
Timeframe: From first dose until 30 days after last dose of SG1827

Arms and interventions

SG1827Experimental

Part A employs a Bayesian Optimal Interval (BOIN) design for dose escalation, with six dose levels of SG1827 (0.3, 1, 3, 6, 10, and 15 mg/kg), starting at 0.3 mg/kg and escalating sequentially from low to high. In Part B, the starting dose of SG1827 in combination with an anti-PD-1/PD-L1 antibody and bevacizumab will be determined by the SMC based on available results from Part A, using a dose-finding strategy that includes a safety run-in cohort followed by adaptive dose de-escalation.

Drugs: SG1827, anti-PD-1/PD-L1 antibody, bevacizumab

Sites

10 sites in 1 country